If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for October 27 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
Ananda Chakrabarty is the holder of the first patent on a genetically-modified organism. Lately he’s turned his sights to a revolutionary new approach to cancer treatment — utilizing proteins from naturally-occuring symbiotic bacteria. These exploits are described in his new book, Bugging Cancer. For centuries mankind has been intimidated by cancer, and research has been […]
Like this:
Like Loading...
November 6, 2013 Comments Off on Cancer remains the dominant disease target for biotech through to 2010 Posted in: General Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
Go to paperABSTRACT: The two leading therapeutic areas for biological products, in t…
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for October 25 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for October 19 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for October 15 2013| Tradename | Applicant | Generic Name | Patent
Expiration |
|---|
PROPECIA | Merck | finasteride | Oct 15, 2013 | *Drugs may be
covered by multiple patents or regulatory protections. See the DrugPatentWatch
database for complete details. |
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
October 28, 2013 Comments Off on Fourth edition of Building Biotechnology coming soon Posted in: General Biotechnology The fourth edition of Building Biotechnology, the premier biotechnology industry primer, is slated for publication in December and is ready for reviewers. Building Biotechnology has been adopted by dozens of educational programs, and is on the nightstands of many biotech CEOs. The book covers a broad range of essential knowledge in business, regulations, patents, law, policy, and science. […]
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for October 13 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for October 8 2013
DrugPatentWatch Serves Your Competitive Intelligence
NeedsSubscribers have
access to valuable datasets, including: - Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information - Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export - More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete detailsDISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Like this:
Like Loading...
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In what can only be described as a slow news period for pharma IP policy, the arcane yet important issue of patent linkage has resurfaced in not once but […]
Like this:
Like Loading...
